Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Ascendis Pharma A/S (ASND)

105.55   -3.37 (-3.09%) 03-22 16:00
Open: 109.33 Pre. Close: 108.92
High: 109.745 Low: 105.41
Volume: 115,196 Market Cap: 6,032(M)

Technical analysis

as of: 2023-03-22 3:46:13 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 133.03     One year: 140.28
Support: Support1: 103.84    Support2: 86.4
Resistance: Resistance1: 113.89    Resistance2: 120.1
Pivot: 109.77
Moving Average: MA(5): 108.56     MA(20): 110.54
MA(100): 116.87     MA(250): 104.73
MACD: MACD(12,26): -2     Signal(9): -2
Stochastic oscillator: %K(14,3): 36.5     %D(3): 40.6
RSI: RSI(14): 38.7
52-week: High: 134.52  Low: 61.57
Average Vol(K): 3-Month: 264 (K)  10-Days: 205 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ASND ] has closed above bottom band by 13.7%. Bollinger Bands are 35.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 111.49 - 112.04 112.04 - 112.48
Low: 105.42 - 106.16 106.16 - 106.76
Close: 107.88 - 109 109 - 109.91

Company Description

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Headline News

Sun, 19 Mar 2023
Validea's Top Ten Healthcare Stocks Based On Peter Lynch - 3/19 ... - Nasdaq

Fri, 17 Mar 2023
Omega Therapeutics, Inc. (OMGA) Moves 15.2% Higher: Will This ... - Nasdaq

Mon, 06 Mar 2023
These Are The Top 10 Holdings Of David Kim - ValueWalk

Mon, 06 Mar 2023
Analysts give Ascendis Pharma A/S (NASDAQ:ASND) a "Moderate ... - Best Stocks

Mon, 20 Feb 2023
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2022 Earnings Call Transcript - Yahoo Finance

Fri, 10 Feb 2023
On Thursday, Ascendis Pharma A/S (ASND) will report earnings. - Best Stocks

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. -314 (M)
Shares Float 0 (M)
% Held by Insiders 5.715e+007 (%)
% Held by Institutions 5.553e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS 3.904e+007
EPS Est Next Qtl 0.01
EPS Est This Year -0.15
EPS Est Next Year 0.14
Book Value (p.s.) -11.07
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -1
Return on Equity (ttm) 97.8
Qtrly Rev. Growth -101.7
Gross Profit (p.s.) 1058.83
Sales Per Share -78.56
EBITDA (p.s.) 5.51948e+006
Qtrly Earnings Growth -5.5604e+008
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio 0
PEG Ratio 814
Price to Book value -9.61
Price to Sales -1.36
Price to Cash Flow 0

Stock Dividends

Dividend 3.28e+006
Forward Dividend 3.16e+006
Dividend Yield 3086770%
Dividend Pay Date 2023-03-16
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.